Valuation: Newron Pharmaceuticals S.p.A.

Market Cap 266M 303M 247M 227M 426M 29.14B 433M 2.94B 1.15B 14.33B 1.14B 1.11B 49.54B P/E 2026 *
-9.41x
P/E 2027 * 34.5x
Enterprise Value 304M 347M 283M 260M 488M 33.38B 496M 3.36B 1.31B 16.41B 1.3B 1.27B 56.75B EV / Sales 2026 *
28.1x
EV / Sales 2027 * 6.26x
Free-Float
86.89%
Yield 2026 *
-
Yield 2027 * -
1 day+0.68%
1 week+4.03%
Current month-8.90%
1 month-6.46%
3 months-27.65%
6 months-44.74%
Current year-50.19%
1 week 11.28
Extreme 11.28
12.32
1 month 11.24
Extreme 11.24
13.18
Current year 11.24
Extreme 11.24
31.85
1 year 6.62
Extreme 6.62
31.85
3 years 4.09
Extreme 4.09
31.85
5 years 1.01
Extreme 1.01
31.85
10 years 0.9
Extreme 0.9
31.85
Manager TitleAgeSince
Chief Executive Officer 62 2012-05-14
Director of Finance/CFO - 2011-12-31
Chief Operating Officer - 2021-12-31
Director TitleAgeSince
Director/Board Member 62 2012-05-14
Director/Board Member - 2023-03-31
Director/Board Member - 2024-04-16
Date Insider Type Main position Quantity % Market Cap.
12/3/25 Fiscal year

Founder

5,465 0.0274%
12/3/25 Sell 5,465 0.0274%
11/27/25 Sell 14,567 0.0730%
Change 5-day change 1-year change 3-year change Capi.($)
+0.68%+4.03%+68.51%+116.79% 300M
+1.07%-4.73%-3.96%+11.63% 46.35B
+0.25%+5.61%+404.21%+606.87% 40.13B
-0.27%+2.67%+10.54%+65.01% 36.33B
+0.35%-1.16%+7.11%-8.85% 34.6B
+3.14%+1.02%+3.72%+34.86% 26.77B
+0.47%-2.29% - - 16.66B
-0.73%+11.80%+37.49%+145.18% 16.91B
+0.42%-4.46%+4.80%+8.67% 13.05B
-2.68%-2.49%-1.27%-32.60% 13.05B
Average +0.27%+1.25%+59.02%+105.29% 24.41B
Weighted average by Cap. +0.46%+0.77%+76.78%+132.13%

Financials

2026 *2027 *
Net sales 10.84M 12.35M 10.08M 9.25M 17.39M 1.19B 17.65M 120M 46.78M 585M 46.35M 45.35M 2.02B 44.83M 51.04M 41.69M 38.26M 71.88M 4.92B 72.99M 495M 193M 2.42B 192M 187M 8.36B
Net income -31.17M -35.49M -28.99M -26.6M -49.99M -3.42B -50.76M -344M -135M -1.68B -133M -130M -5.81B 5.02M 5.72M 4.67M 4.29M 8.05M 551M 8.18M 55.47M 21.67M 271M 21.47M 21.01M 936M
Net Debt 38.68M 44.04M 35.98M 33.01M 62.03M 4.24B 62.98M 427M 167M 2.09B 165M 162M 7.21B 14.72M 16.76M 13.69M 12.56M 23.6M 1.61B 23.96M 163M 63.5M 793M 62.9M 61.55M 2.74B
Logo Newron Pharmaceuticals S.p.A.
Newron Pharmaceuticals SpA is an Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.
Employees
27
Date Price Change Volume
26-07-24 CHF 11.88 +0.68% 32,026
26-07-23 CHF 11.80 -2.48% 48,361
26-07-22 CHF 12.10 +3.42% 56,666
26-07-21 CHF 11.70 +2.81% 25,365
26-07-20 CHF 11.38 -1.73% 24,326
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
12.77EUR
Average target price
51.43EUR
Spread / Average Target
+302.63%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NWRN Stock